New Products: Once-a-month Actonel option approved

Article

Once monthly dose of Actonel has been approved to treating and preventing postmenopausal osteoporosis.

The Agency okayed the new dosage on the basis of a study of 642 women that compared 150 mg of Actonel monthly to 5 mg daily of the tablet. The study showed similar increases for both groups in lumbar spine bone mineral density and at other sites from baseline at 1 year. Produced by Procter and Gamble Pharmaceuticals, the drug is marketed by Sanofi-Aventis U.S. For more information on Actonel, visit the Web site at http://www.actonel.com/.

Recent Videos
Devon Ramaeker, MD
Elizabeth Gandee, APRN-CNP, highlights gaps in women's menopause knowledge | Image Credit: wexnermedical.osu.edu
Doula highlights how postpartum care is failing new mothers | Image Credit: linkedin.com
Nicky Herrick MD; and Anushree Agarwal, MD, MBBS, highlight their study on cardiac arrhythmias in pregnancy | Image Credit: © Igor Borodin - stock.adobe.com.
Lisa Becht, MD, FACOG, sheds light on fertility awareness | Image Credit: havingbabies.com.
First US national HPV conference highlights advances in cancer prevention | Image Credit: uchealth.com.
Mitchell Creinin, MD, reports estetrol pill eases menstrual symptoms | Image Credit: health.ucdavis.edu
1 expert is featured in this series.
Susanna Mitro, PhD, reveals ethnic disparities in uterine fibroid diagnosis | Image Credit: divisionofresearch.kaiserpermanente.org.
Shayna Mancuso, DO, highlights the real impact of menopause | Image Credit: linkedin.com.
Related Content
© 2025 MJH Life Sciences

All rights reserved.